

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
23 December 2009 (23.12.2009)

PCT

(10) International Publication Number
WO 2009/155257 A8(51) International Patent Classification:
A61K 38/00 (2006.01)(21) International Application Number:
PCT/US2009/047437(22) International Filing Date:
16 June 2009 (16.06.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/073,193 17 June 2008 (17.06.2008) US
61/078,165 3 July 2008 (03.07.2008) US
61/090,415 20 August 2008 (20.08.2008) US(71) Applicant (for all designated States except US): **INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION** [US/US]; 351 West 10th Street, Indianapolis, IN 46202 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **DIMARCHI, Richard, D.** [US/US]; 10890 Wilmington Drive, Carmel, IN 46033 (US). **SMILEY, David, L.** [US/US]; 3823 South Laura Way, Bloomington, IN 47401 (US). **DIMARCHI, Maria** [US/US]; 10890 Wilmington Drive, Carmel, IN 46033 (US). **CHABENNE, Joseph** [US/US]; 13505 East 114th Street, Fishers, IN 46037 (US). **DAY, Jonathan** [US/US]; 1331 South Adams Street, Apt. 11, Bloomington, IN 47402 (US).(74) Agent: **ADDISON, Bradford, G.**; Barnes & Thornburg LLP, 11 South Meridian Street, Indianapolis, IN 46204 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,

[Continued on next page]

(54) Title: GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS

Figures 11A



(57) Abstract: Modified glucagon peptides are disclosed having improved solubility and/or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.



NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

- (48) Date of publication of this corrected version:**

25 March 2010

- (15) Information about Correction:**

see Notice of 25 March 2010